[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"spinal-cord-injuries\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:spinal-cord-injuries":27},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,167,0,25,[9,41,64,85,105,127,160,244,276,300,332,352,375,395,419,447,469,496,517,538,560,592,614,639,664],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100584641","effects-of-a-mobile-app-based-mindfulness-intervention-in-persons-with-spinal-cord-injury-and-chronic-pain-100584641",false,"NCT06891989","Effects of a Mobile App-Based Mindfulness Intervention in Persons With Spinal Cord Injury and Chronic Pain","Effects of a Mobile App-Based Mindfulness Intervention in Persons With Spinal Cord Injury and Chronic Pain: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Traumatic SCI of at least 6 months duration\n* Chronic pain \\[defined as pain lasting at least 3 months with a pain intensity rating of 4 or higher on a 10-point visual analog scale\\]\n* Understand spoken and written English sufficiently to provide informed consent, participate in the intervention and complete study surveys\n\nExclusion Criteria:\n\n* Lack of daily internet access\n* Inability to demonstrate comprehension of informed consent by correctly answering 4 out of 5 questions about the study\n* Significant visual\u002Fhearing impairment that does not allow use of the MM app's audiovisual presentations\n* Use of any meditation more than once a week in the last 3 months\n* Inability to provide or obtain an email address for registration to the AC intervention and\u002For communication with study staff\n* Inability to provide a phone number for communication with study staff","ALL","18 Years",{"count":20,"type":21},282,"ESTIMATED","INTERVENTIONAL",[24],"NA","The purpose of this study is to evaluate the efficacy of a 6-week app-guided MM intervention compared to a 6-week app-guided health education AC condition on pain intensity, pain interference, depression, and anxiety.",[27],"Spinal Cord Injuries","NOT_YET_RECRUITING","2026-08-18",{"date":31,"type":32},"2026-08-20","ACTUAL",{"date":34,"type":21},"2026-10",{"date":36,"type":21},"2029-12-30",{"name":38,"class":39},"Mayo Clinic","OTHER",1,{"id":42,"slug":43,"hasResults":12,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":22,"phases":50,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":63},"100526869","happiness-changing-the-perceived-pain-intensity-in-populations-with-spinal-cord-injury-and-with-health-disparities-a-feasibility-study-100526869","NCT06140355","cHAnging the Perceived Pain INtensity in divErSe Populations With Spinal Cord Injury","HAPPINESS: cHAnging the Perceived Pain INtEnSity in Populations With Spinal Cord Injury and With Health Disparities: A Feasibility Study","Inclusion Criteria:\n\n* 18+ years old\n* medically stable\n* with neuropathic pain 4 or above on the numeric pain rating scale + screened with painDETECT\n* willing to participate in a remote Qigong intervention (from any location with internet connection)\n* fluent in English or Spanish\n* access to the internet and a computer\u002FiPad or smartphone\n\nExclusion Criteria:\n\n* uncontrolled seizure disorder\n* cognitive impairment and\u002For communicative disability (e.g., due to brain injury) preventing them from following directions or from learning\n* ventilator dependency\n* major medical complications\n* pressure ulcers hindering prolonged sitting or lying down\n* (planning to become) pregnant or planning a major surgery during the study (given study duration, regular Qigong practice, and frequent check-ins)\n* regular Tai Chi or Qigong practice in the past 6 months (3x\u002Fweek or more)\n* currently engaged in other rehabilitation programs that would influence outcomes",{"count":49,"type":21},40,[24],"Chronic neuropathic pain affects 69% of adults with spinal cord injury (SCI). Current treatment options are limited (primarily pain medications) with insufficient benefits and significant risks for addiction and adverse effects. Of the available mind and body approaches, Qigong is the most accessible for adults with SCI with evidence for effectiveness in reducing pain, but there is insufficient evidence to make recommendations for adults with SCI. Thus, the feasibility of Qigong in SCI needs to be established.\n\nTo support our feasibility study, we investigated a 12-week remote Qigong program in adults with SCI and neuropathic pain. We recruited 23 adults with SCI, 18 completed the study, and 12 completed the 1-year follow-up. They practiced Qigong 138% of the required intensity (which was, at least 3x\u002Fweek with Qigong video through the internet). Their pain was reduced by 44% after 12 weeks of Qigong practice and was still reduced at the 6-week and 1-year follow-up. However, three key elements need to be addressed before performing a larger effectiveness study: (1) feasibility\u002Facceptability of Qigong from adults with SCI of diverse backgrounds; (2) feasibility of the study design with control group); and (3) objective outcome measures.\n\nThis R34 feasibility study, the HAPPINESS trial (cHAnging the Perceived Pain INtensity in divErSe populations with Spinal cord injury), will expand on our prior study to consolidate feasibility with a rigorous protocol. We will address the following aims: AIM 1. Identify the facilitators\u002Fbarriers to participating in a Qigong study through focus groups\u002Finterviews with stakeholders from diverse backgrounds, defined as Hispanics, veterans, and adults living in rural, underserved areas. AIM 2. Establish the feasibility of study design\u002Fmethods of the HAPPINESS trial in adults with SCI (at least 50% of diverse backgrounds) through pre-specified targets for recruitment\u002Fenrollment, feasibility, and acceptability of design and outcomes. Using a Phase I randomized controlled trial design, 40 adults with SCI-related neuropathic pain will be randomized to 12-week remote Qigong intervention OR a short daily pain management survey that can be completed on phone\u002FiPad\u002Fcomputer + 6-month follow-up. The study results will facilitate a rigorous structure to design larger effectiveness studies and facilitate a clear pathway for researchers to investigate Qigong and other mind-body approaches for whole-person health in diverse groups of adults with chronic\u002Fneurological disorders.",[27],"RECRUITING","2026-08-17",{"date":56,"type":32},"2026-08-19",{"date":58,"type":32},"2024-08-20",{"date":60,"type":21},"2027-01-31",{"name":62,"class":39},"University of Minnesota",3,{"id":65,"slug":66,"hasResults":12,"nctId":67,"briefTitle":68,"officialTitle":68,"acronym":4,"eligibilityCriteria":69,"healthyVolunteers":12,"sex":17,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":4,"studyType":22,"phases":74,"briefSummary":75,"conditions":76,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":40},"100459848","closed-loop-spinal-stimulation-for-restoration-of-upper-extremity-function-after-spinal-cord-injury-100459848","NCT05267951","Closed-loop Spinal Stimulation for Restoration of Upper Extremity Function After Spinal Cord Injury","Inclusion Criteria:\n\n1. has cervical (C8 or higher), incomplete (American Spinal Cord Injury Impairment Scale - C or D) traumatic spinal cord injury, minimum 1-year post-injury\n2. has difficulty with hand functions in activities of daily living (e.g., dressing, grooming, feeding)\n3. stable medical condition without cardiopulmonary disease or autonomic dysreflexia that would contraindicate participation in upper extremity rehabilitation or testing activities\n4. capable of performing simple cued motor tasks\n5. has ability to attend intervention\u002Ffunctional task training and assessment sessions 3 times\u002Fweek\n6. has adequate social support to participate in all intervention and baseline\u002Ffollow-up assessment sessions throughout 40 weeks.\n7. has ability to read and speak English\n\nExclusion Criteria:\n\n1. dependent on ventilation support\n2. has implanted stimulator (e.g., pacemaker, vagus nerve stimulator, cochlear implant, etc.) or baclofen pump\n3. has metallic devices and implants in the head (e.g., deep brain stimulators, aneurysm clips\u002Fcoils, and stents, vagus nerve stimulators)\n4. has a history or current signs\u002Fsymptoms of syringomyelia (progressive pain, muscle weakness, and\u002For sensory loss; deterioration of bowel\u002Fbladder function)\n5. has autoimmune etiology of spinal cord dysfunction\u002Finjury\n6. has received botulinum toxin injections in upper extremity muscles in the prior 6 months\n7. has tendon transfer or nerve transfer surgery in the upper extremity,\n8. taking tizanidine, dantrolene or diazepam\n9. has history of seizures or increased risk for seizures\n10. has history of chronic headaches or migraines\n11. has history of neurologic diseases, such as stroke, multiple sclerosis, traumatic brain injury, etc.\n12. has peripheral neuropathy (diabetic polyneuropathy, entrapment neuropathy, etc.)\n13. has rheumatic diseases (rheumatoid arthritis, systemic lupus erythematosus, etc.)\n14. has significant medical disease; including uncontrolled systemic hypertension with values above 170\u002F100 mmHg; cardiac or pulmonary disease; uncorrected coagulation abnormalities or need for therapeutic anticoagulation\n15. has cardiovascular or musculoskeletal disease or injury that would prevent full participation in physical therapy intervention\n16. unhealed fracture, contracture, pressure sore, or frequent urinary tract infections or other illnesses that might interfere with upper extremity rehabilitation or testing activities\n17. has a history of severe allergy (i.e., allergic reaction that could not be treated with antihistaminic medication\n18. has alcohol and\u002For drug abuse (subject's verbal statement)\n19. has cancer\n20. pregnant (Childbearing potential will be asked at screening, baseline, and every subsequent visit in which the subject would receive transcutaneous spinal cord stimulation and\u002For Transcranial Magnetic Stimulation whether the participant could be pregnant. Pregnancy will be ruled out by an over-the-counter urine pregnancy test for all females of childbearing potential (1) at the time of enrollment, (2) prior to all sessions that include Transcranial Magnetic Stimulation, and also prior to the intervention phases of (3) closed-loop or (4) open-loop stimulation. Additional pregnancy tests may be performed if there is a concern of pregnancy.)\n21. lack of ability to fully comprehend, cooperate and\u002For safely perform study procedures in the investigator's opinion\u002Fjudgment\n22. unable to read and\u002For comprehend the consent form","21 Years","70 Years",{"count":73,"type":21},9,[24],"The purpose of this study is to assess the efficacy of non-invasive (transcutaneous) closed-loop electrical spinal cord stimulation for recovery of upper limb function (Aim 1) and spasticity (Aim 2) following spinal cord injury.",[27],"2026-08-14",{"date":29,"type":32},{"date":80,"type":32},"2022-10-12",{"date":82,"type":21},"2028-06-30",{"name":84,"class":39},"University of Washington",{"id":86,"slug":87,"hasResults":12,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":71,"enrollmentInfo":92,"targetDuration":4,"studyType":22,"phases":94,"briefSummary":95,"conditions":96,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":40},"100547352","brain-controlled-spinal-stimulation-walking-therapy-after-incomplete-spinal-cord-injury-sci-100547352","NCT06406855","Brain-Controlled Spinal Stimulation Walking Therapy After Incomplete Spinal Cord Injury (SCI)","Brain-Controlled Spinal Stimulation Therapy for Restoration of Walking After Incomplete Spinal Cord Injury (SCI)","Inclusion Criteria:\n\n1. At least 18 years old and no older than 70 years old at the time of enrollment.\n2. Traumatic incomplete spinal cord injury (neurological level at or above T10 spinal cord level; Abbreviated Injury Scale (AIS) C or D impairment grade for group 1, 3 and 4 and AIS B, C or D impairment grade for group 2), who are more than 6 months post-injury.\n3. Has detectable motor function in at least 2 muscles per side confirmed by voluntary Electromyography (EMG) or detectable tibialis anterior (TA) muscle motor evoked potentials (MEPs) at the baseline assessment.\n4. Able to commit to intensive training and assessment sessions over a maximum total duration of 6 months.\n5. Could effectively walk overground for at least 10 meters with some assistance of a therapist and minimal body-weight support, with functional spasticity (by participant's self-report), functional range-of-motion of lower limb joints, and acceptable bone mass to enable body-weight support, confirmed by Dual-energy X-ray absorptiometry (DXA) scan.\n\nExclusion Criteria:\n\n1. Has traumatic brain injury, stroke, multiple sclerosis, or other neuromuscular disorders that could affect neuromotor function and walking.\n2. Has severe spasticity that could prevent stepping and walking function determined by the investigator.\n3. Has major executive dysfunction, dementia, depression, neurocognitive impairments, or other major medical co-morbidities.\n4. Has other contra-indications for transcranial magnetic stimulation (TMS) or Transcutaneous Spinal Cord Stimulation (TSCS).\n5. Has a history of recent seizures or poorly managed autonomic dysreflexia that could be triggered by TMS or TSCS.\n6. Has a history of prior intracranial surgery or known lesions that would limit TMS assessments and Brain-Computer Interface (BCI) recordings.\n7. Individuals with metal implants in their head and other implantable devices in the body that could be affected by TMS or TSCS.\n8. Has peripheral neuropathy (diabetic polyneuropathy, entrapment neuropathy, etc.).\n9. Has urinary tract infection, unhealed fracture, contracture, and pressure sore (Braden Scale).\n10. Has breakdown in skin area that will come into contact with electrodes.\n11. Individuals who require therapy or other care that could interfere with participation in the study.\n12. Individuals on investigational drugs or any other intervention known to have a potential impact on neuromotor function.\n13. Individuals with substance disorders, including alcoholism and drug abuse.\n14. Individuals who are pregnant, breastfeeding, or the desire to become pregnant during the study.\n15. In the opinion of the investigators, the study is not safe or appropriate for the participant.",{"count":93,"type":21},12,[24],"The purpose of this research is to test the effectiveness of a new therapy, called Brain-Computer Interface (BCI)-Transcutaneous Spinal Cord Stimulation (TSCS), for improving walking in people with an incomplete spinal cord injury (SCI).",[27],"2026-08-12",{"date":77,"type":32},{"date":100,"type":32},"2024-05-07",{"date":102,"type":21},"2026-12-31",{"name":104,"class":39},"University of Miami",{"id":106,"slug":107,"hasResults":12,"nctId":108,"briefTitle":109,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":22,"phases":115,"briefSummary":116,"conditions":117,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":119,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":40},"100466291","mild-intermittent-hypoxia-a-prophylactic-for-autonomic-dysfunction-in-individuals-with-spinal-cord-injuries-100466291","NCT05351827","Mild Intermittent Hypoxia: A Prophylactic for Autonomic Dysfunction in Individuals With Spinal Cord Injuries","MIH and AD","Inclusion Criteria:\n\n* Motor incomplete spinal cord injury at or above the 12th thoracic vertebrae\n* Signs or symptoms of autonomic dysfunction (this will be determined by the Autonomic Dysfunction Following Spinal Cord Injury (ADFSCI) and ISAFSCI questions. The ADFSCI requires a score of 1 on questions 16 and 22, and the International Standards to document Autonomic Function following SCI (ISAFSCI) requires a score of 1 on any parameter)\n* Chronic injuries (\\>1 year post injury)\n\nExclusion Criteria:\n\n* Pregnant\n* Smoker\n* Drug addiction\n* Complete spinal cord injury\n* Spinal cord injury below the 6th thoracic vertebrae\n* Insulin dependent diabetes\n* Shift workers (i.e., disrupted circadian rhythm)\n* Active skin breakdown or pressure sores","60 Years",{"count":114,"type":21},24,[24],"The prevalence of autonomic dysfunction and sleep disordered breathing (SDB) is increased in individuals with spinal cord injury (SCI). The loss of autonomic control results in autonomic dysreflexia (AD) and orthostatic hypotension (OH) which explains the increase in cardiovascular related mortality in these Veterans. There is no effective prophylaxis for autonomic dysfunction. The lack of prophylactic treatment for autonomic dysfunction, and no best clinical practices for SDB in SCI, are significant health concerns for Veterans with SCI. Therefore, the investigators will investigate the effectiveness of mild intermittent hypoxia (MIH) as a prophylactic for autonomic dysfunction in patients with SCI. The investigators propose that MIH targets several mechanisms associated with autonomic control and the co-morbidities associated with SDB. Specifically, exposure to MIH will promote restoration of homeostatic BP control, which would be beneficial to participation in daily activities and independence in those with SCI.",[27,118],"Autonomic Dysreflexia",{"date":77,"type":32},{"date":121,"type":32},"2022-10-01",{"date":123,"type":21},"2027-10-29",{"name":125,"class":126},"VA Office of Research and Development","FED",{"id":128,"slug":129,"hasResults":12,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":112,"enrollmentInfo":134,"targetDuration":4,"studyType":22,"phases":136,"briefSummary":137,"conditions":138,"keywords":143,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":40},"100650652","zepu-ai-series-limb-feedback-robot-training-study-zepuaisrct-100650652","NCT07749625","ZEPU-AI Series Limb Feedback Robot Training Study (ZEPUAISRCT)","Feasibility, Safety and Efficacy of ZEPU-AI2, AI4, AI6 Plus and AI7A Robotic Rehabilitation Systems in Patients With Upper and Lower Limb Motor Dysfunction","Inclusion Criteria:\n\n* Presence of upper-limb motor dysfunction, with or without concurrent lower-limb impairment, due to one of the following conditions: (a) Stroke, with onset between 2 and 24 months prior to enrollment; (b) Incomplete spinal cord injury (ASIA Scale B, C, or D); (c) Traumatic brain injury; or (d) Orthopedic disorders affecting upper and\u002For lower limb motor function\n* Age between 18 and 60 years\n* Ability to understand study procedures and follow instructions, and to provide written informed consent (or assent with guardian consent where applicable)\n* Body weight and limb anthropometry compatible with ZEPU-AI2, AI4, AI6 Plus, and AI7A systems, as per manufacturer specifications\n* Medically stable and cleared by a physician for robotic rehabilitation, with no active infection, uncontrolled cardiac or respiratory disease, severe osteoporosis, uncontrolled epilepsy, or untreated deep vein thrombosis\n\nExclusion Criteria:\n\n* Complete spinal cord injury or profound motor paralysis preventing safe interaction with robotic devices\n* Severe cognitive impairment, defined as a Mini-Mental State Examination (MMSE) score \\\u003C 24, that would compromise safe participation\n* Severe spasticity of the upper limb, defined as a Modified Ashworth Scale score \\> 3\n* Unstable fractures, severe fixed joint contractures of the shoulder, elbow, wrist, or hand (e.g., \\> 30°), or severe pain limiting safe robotic training\n* Uncontrolled cardiac arrhythmia, presence of a pacemaker, or other implanted electronic medical devices incompatible with robotic sensors\n* Pregnancy",{"count":135,"type":21},36,[24],"The goal of this clinical trial is to learn whether robotic rehabilitation devices (ZEPU-AI2, AI4, AI6 Plus, and AI7A) are feasible, safe, and effective for adults with upper or lower limb motor problems. These problems can result from stroke, incomplete spinal cord injury, traumatic brain injury, or orthopedic surgery. The main questions it aims to answer are:\n\nIs robotic rehabilitation training safe and practical to deliver alongside conventional therapy? Does adding robotic-assisted therapy improve motor function, balance, gait, and independence in daily activities compared to conventional rehabilitation alone? What side effects or device-related problems, if any, occur during robotic training?\n\nThe Investigators will compare a robotic-augmented rehabilitation group to a control group receiving conventional rehabilitation alone, to see if adding robotic therapy leads to better recovery.\n\nParticipants will:\n\nReceive robotic-assisted therapy sessions three times a week for 12 weeks, each lasting about 45 minutes (robotic group), or continue with conventional rehabilitation alone (control group) Undergo assessments of movement, balance, walking ability, and daily function before and after the study period Be monitored for any side effects or complications related to the device or training",[139,27,140,141,142],"Stroke","Brain Injuries, Traumatic","Movement Disorder, Upper Extremity","Movement Disorder, Lower Extremity",[144,145,146,147,148,149,150],"Robotic Rehabilitation","ZEPU-AI2","ZEPU-AI4","ZEPU-AI6 Plus","ZEPU-AI7A","Neurorehabilitation","Musculoskeletal Rehabilitation","2026-08-04",{"date":153,"type":32},"2026-08-06",{"date":155,"type":21},"2026-08",{"date":157,"type":21},"2026-11",{"name":159,"class":39},"Bangladesh Medical University",{"id":161,"slug":162,"hasResults":12,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":166,"eligibilityCriteria":167,"healthyVolunteers":12,"sex":168,"minAge":18,"maxAge":4,"enrollmentInfo":169,"targetDuration":4,"studyType":22,"phases":171,"briefSummary":174,"conditions":175,"keywords":189,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":243},"100650026","phase-2-testosterone-therapy-with-or-without-finasteride-after-spinal-cord-injury-trt-sci-trial-100650026","NCT07742553","Testosterone Therapy With or Without Finasteride After Spinal Cord Injury: TRT-SCI Trial","A Multisite, Double-blind, Randomized Controlled Trial Comparing Body Composition, Muscle, and Bone Changes to TestosteRone Therapy With or Without Finasteride After Spinal Cord Injury: TRT-SCI Trial","TRT-SCI","Inclusion Criteria:\n\n* Veterans eligible for care within the Veterans Health Administration (VHA)\n* Diagnosis of motor incomplete SCI (AIS C-D) for \\>24-months involving spinal segment lumbar (L)1 or above from trauma, vascular, or orthopedic pathology\n* Low total testosterone (\\\u003C300 nanograms\u002Fdecilliter \\[ng\u002FdL\\]) and\u002For low free testosterone (\\\u003C4.6 ng\u002FdL)\n* Presence of one or more sign of low testosterone, defined as:\n\n  * decreased energy\n  * motivation\n  * initiative or self-confidence\n  * increased fatigue or tiredness\n  * reduced sexual desire or activity\n  * decreased spontaneous (e.g., morning) erections or erectile dysfunction\n  * loss of body hair or reduced shaving\n  * feeling sad or blue or having a depressed mood or a persistent low-grade depressive disorder (defined as a score of \\>3 on the Patient Health Questionnaire \\[PHQ\\]-2)\n  * hot flashes\n  * fatigue or irritability\n  * poor concentration or memory\n  * mild unexplained (normocytic-normochromic) anemia, defined as hematocrit (HCT) \\\u003C40%, hemoglobin \\\u003C13.6 grams\u002Fdeciliter (g\u002FdL), or red blood cell count \\\u003C4.5 million\u002Fmicroliter (mcL)\n  * sleep disturbances or increased sleepiness\n  * reduced muscle bulk, strength, or physical function\n  * increased body fat or body mass index\n* Presence of motor impairment, defined as self-selected walking pace ≤1.0 meters\u002Fsecond (m\u002Fs) on a 10-meter walk test (10mWT), with or without gait devices or braces and with or without assistance from another person, or as self-selected walking pace \\>1.0 m\u002Fs with reliance on a gait device or brace or with highly compensated movement impairment identified by a trained observer\n* Medically stable condition asymptomatic for bladder infection, major decubiti, cardiopulmonary disease, or other significant condition that will interfere with the study\n* Documented approval from a physician verifying medical status\n\nExclusion Criteria:\n\n* Involvement in another research study that may influence outcomes\n* Mental state that precludes understanding the protocol\n* Life expectancy \\\u003C12 months\n* History of or current congenital spinal cord injury (SCI) (e.g., Chiari malformation, myelomeningocele, intraspinal neoplasm, Friedreich's ataxia) or degenerative spinal disorder (e.g., spinocerebellar degeneration) that may complicate procedures\n* Amyotrophic lateral sclerosis, multiple sclerosis, or other neurologic injury \u002F impairment that may complicate procedures\n* Current cancer diagnosis\n* History of prostate or breast cancer\n* Any diagnosed or treated cancer in the past 24 months, except basal or squamous cell carcinoma of the skin that has been successfully treated\n* Any major lower-limb fracture in the past 12 months\n* Unevaluated circulating prostate-specific antigen (PSA) \\>4.0 nanograms\u002Fmilliliter (ng\u002FmL) or \\>3.0 ng\u002FmL in men with prostate cancer risk factors, including agent orange exposure, first degree relative with prostate cancer, or African American background\n* Currently seeking fertility or expected during the study\n* Diagnosed gynecomastia\n* Hematocrit (HCT) \\>48%\n* Any major cardiovascular event in the last 6 months, defined as:\n\n  * an acute myocardial infarction\n  * any cardiac revascularization procedure including stenting\n  * angioplasty or coronary artery bypass grafting\n  * revascularization of the carotid or middle cerebral artery or procedure to treat critical limb ischemia\n  * hospitalization due to unstable angina\n  * transient ischemic attack\n  * stroke\n  * peripheral vascular disease\n* Any angina that is not controlled on a current medical regimen (Canadian class II, III, or IV)\n* Poorly compensated congestive heart failure (New York Heart Association \\[NYHA\\] class III or IV)\n* Poorly controlled hypertension when on medication (consistent systolic BP ≥160 mmHg or diastolic BP ≥100 mmHg)\n* Poorly controlled arrhythmia of any type\n* Severe valvular heart disease\n* Baseline electrocardiogram findings such as left bundle branch block or marked abnormality that precludes serial screening for occult ischemic events\n* History of unprovoked deep venous thrombosis, unprovoked pulmonary embolism, history of recurrent deep venous thrombosis or known thrombophilia\n* Major non-cardiovascular surgery (e.g., major abdominal or thoracic procedure) within 90 days before screening or a major surgery scheduled at the time of screening\n* Liver enzymes (aspartate aminotransferase \\[AST\\] or alanine aminotransferase \\[ALT\\]) \\>1.5 times the normal upper limit\n* Severe or end-stage chronic kidney disease defined as eGFR \\\u003C30 milliliters\u002Fminute (mL\u002Fmin)\n* Diagnosed, but untreated severe obstructive sleep apnea\n* Use of an agent that alters sex-steroid metabolism in the past 90 days, such as: testosterone therapy (TRT), compounded or over-the-counter androgenic hormone or androgen precursor, 5-alpha reductase (5AR) inhibitors, growth hormone, clomiphene, aromatase inhibitors, anti-estrogen or estrogen treatment, or others\n* Use of anti-resorptive or bone anabolic drug therapy in the past 180 days\n* Acute use (\\>5 days) of any opioid (e.g., oxycodone, hydrocodone) or systemic glucocorticoids \\>7.5 milligrams (mg)\u002Fday prednisone equivalent (e.g., hydrocortisone 30 mg, methylprednisolone 6 mg, or dexamethasone 1.2 mg) in the week before screening, except for men who are taking these for a chronic condition and who are anticipated to continue these for the study duration\n* Known allergy to any TRT component (e.g., cottonseed oil or other)\n* Any other condition, lab abnormality, therapy, medical or psychiatric condition, or reason that might pose a risk to the participant, make participation not in the person's best interest, confound the study results (e.g., inability to comply with study requirements), make the participant unsuitable to receive a study intervention, or interfere with their ability to participate for the full study duration","MALE",{"count":170,"type":21},300,[172,173],"PHASE2","PHASE3","Spinal cord injury (SCI) results in lower limb muscle loss, bone loss, and high fat mass that impede the recovery of physical function, increase bone fracture risk, and worsen health and quality of life. These deficits result from reduced activity after SCI and may be worsened by low testosterone, which is present in many men with SCI. In older men with low testosterone who do not have SCI, testosterone therapy (TRT) is known to increase muscle mass, muscle strength, and bone mineral density, and to reduce body fat. However, it is not known if TRT is effective in men with SCI. The purposes of this study are to determine the effectiveness of TRT in men who have low testosterone and difficulty walking after chronic motor incomplete SCI and to assess whether a process in the body that changes testosterone to dihydrotestosterone (DHT; another hormone that is stronger than testosterone) impacts the effectiveness of TRT in the impaired lower limbs and in other tissues after SCI. The researchers hypothesize that TRT will improve muscle and bone in the impaired limbs of men with chronic incomplete SCI and reduce fat mass, and that finasteride (a drug that blocks that blocks a process that changes testosterone to DHT) will influence prostate symptoms but not the musculoskeletal or body composition benefits produced by TRT.",[176,27,177,178,179,180,181,182,183,184,185,186,187,188],"Spinal Cord Injury","Injuries, Spinal Cord","Spinal Cord Contusion","Spinal Cord Trauma","Trauma, Nervous System","Wounds and Injuries","Spinal Cord Compression","Nervous System Diseases","Spinal Cord Diseases","Gonadal Disorders","Endocrine System Diseases","Hypogonadism","Genital Diseases, Male",[190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,213,214,215,216,217,218,219,220,221,222,223,224,225,226,227,228,176,229,230,231,232,233,27,180,181,234,183,184,185,186,187,188,235],"Testosterone","Testosterone cypionate","Testosterone enanthate","Testosterone 17 beta-cypionate","Testosterone undecanoate","Methyltestosterone","Testosterone propionate","Dihydrotestosterone","Androgens","Hormones","Hormone Substitutes, and Hormone Antagonists","Physiologic Effects of Drugs","Pharmacologic Actions","Therapeutic Uses","Anabolic Agents","Testosterone Therapy","Testosterone Replacement Therapy","Dual Energy X ray Absorptiometry","Lean Tissue Mass","Body Composition","Lipid and Glucose profile","Muscle Strength","5-alpha Reductase","Muscle Mass","Bone Mineral Density","Adipose Tissue","Fat Mass","Body Fat","Density, Bone","Bone Formation","Bone Resorption","Bone Density Conservation Agents","Muscle, Skeletal","Bone and Bones","Gait","Walking","Locomotion","Motor Activity","Finasteride","Genital Diseases","Urogenital Diseases","Male Urogenital Diseases","Bone Diseases","Musculoskeletal Diseases","Central Nervous System Diseases","Steroids","2026-08-03",{"date":151,"type":32},{"date":239,"type":21},"2027-10-01",{"date":241,"type":21},"2032-03-31",{"name":125,"class":126},4,{"id":245,"slug":246,"hasResults":12,"nctId":247,"briefTitle":248,"officialTitle":249,"acronym":4,"eligibilityCriteria":250,"healthyVolunteers":12,"sex":17,"minAge":251,"maxAge":252,"enrollmentInfo":253,"targetDuration":4,"studyType":22,"phases":254,"briefSummary":255,"conditions":256,"keywords":265,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":268,"startDateStruct":270,"completionDateStruct":272,"leadSponsor":274,"locationsCount":40},"100373633","closed-loop-deep-brain-stimulation-for-refractory-chronic-pain-100373633","NCT04144972","Closed-Loop Deep Brain Stimulation for Refractory Chronic Pain","Closed-Loop Deep Brain Stimulation for Refractory Chronic Pain Using Summit RC+S","Inclusion Criteria:\n\n1. Age 22-80 years old\n2. Clinical diagnosis of a refractory chronic pain syndrome including\n\n   1. post-traumatic pain syndromes (e.g. root avulsions, nerve crush injuries, spinal cord injury)\n   2. postsurgical pain syndromes (e.g., postmastectomy syndrome, post-thoracotomy syndrome, phantom limb pain, post-surgical spinal pain)\n   3. postherpetic neuralgia\n   4. complex regional pain syndrome\n   5. atypical facial pain\n   6. central pain syndromes (e.g. post-stroke pain, multiple sclerosis pain, post-radiation pain)\n   7. post-radiation plexopathy\n3. Two or more years or more of medically refractory severe pain\n4. Average daily pain for the past 30 days reported as \\>6 on a 0-10 numeric rating scale (NRS)\n5. Pain that fluctuates over a range of at least 3 points on the NRS\n6. Patient has failed at least two pain medications from different classes as determined by a neurologist or pain management specialist with stable doses of medications for 30 days prior to baseline visit.\n7. Lack of a surgically correctible etiology for the pain as determined by 2 independent surgeons\n8. Ability to speak \u002F read English\n9. Capable of understanding and providing informed consent\n10. Absence of significant cognitive impairment - score of 25 or greater on the Montreal Cognitive Assessment (MoCA)\n11. Successful detection of pain biomarkers or positive symptomatic response to inpatient stimulation trial period if performed.\n\nExclusion Criteria:\n\n1. Major medical co-morbidities increasing the risk of surgery including uncontrolled hypertension, coagulopathy, severe diabetes, major organ system failure, active infection or history of implant related infections, immunocompromised state or malignancy with \\\u003C 5 years life expectancy\n2. Presence of cardiac pacemakers\u002Fdefibrillators, implanted medication pumps, intra-cardiac lines, any intracranial implants (e.g., aneurysm clip, shunt, cochlear implant, electrodes) or other implanted stimulators not compatible with RC+S system\n3. Pregnancy or breast feeding: all women of child bearing potential will have a negative urine pregnancy test prior to undergoing their surgical procedure.\n4. Active depression (BDI \\> 20), Suicide attempt \\\u003C\u002F= 12 months or imminent suicide risk, or other untreated or uncontrolled psychiatric illness that evaluating psychiatrist would recommend exclusion of patient after neuropsychiatric evaluation.\n5. History of substance abuse in past 3 years\n6. Inability to stop anticoagulation or platelet anti-aggregation therapy for surgery and recovery.\n7. Implantable hardware not compatible with MRI or with the study.\n8. MR abnormalities that suggest an alternative diagnosis or contraindicate surgery\n9. Previous cranial ablative surgery.\n10. Previous deep brain stimulation surgery using an RC+S incompatible system\n11. Major neurological disorder other than the one that led to the chronic pain including epilepsy or a neurodegenerative condition including inability to recharge the device.\n12. Requires diathermy, electroconvulsive therapy (ECT) or transcranial magnetic stimulation (TMS)\n13. Allergies or known hypersensitivity to materials in the Summit RC+S system\n14. Patients may be excluded from enrollment due to a condition that, in the judgment of the PI, significantly increases risk or reduces significantly the likelihood of benefit from DBS.","22 Years","80 Years",{"count":93,"type":21},[24],"Chronic pain affects 1 in 4 US adults, and many cases are resistant to almost any treatment. Deep brain stimulation (DBS) holds promise as a new option for patients suffering from treatment-resistant chronic pain, but traditional approaches target only brain regions involved in one aspect of the pain experience and provide continuous 24\u002F7 brain stimulation which may lose effect over time. By developing new technology that targets multiple, complimentary brain regions in an adaptive fashion, the investigators will test a new therapy for chronic pain that has potential for better, more enduring analgesia.",[27,257,258,259,260,261,262,263,264],"Nerve Injury","Pain, Postoperative","Post Herpetic Neuralgia","Complex Regional Pain Syndromes","Post-Stroke Pain","Post Radiation Brain Injury","Post Radiation Plexopathy","Nerve Root Avulsion",[266],"Chronic Pain","2026-07-29",{"date":269,"type":32},"2026-07-31",{"date":271,"type":32},"2019-10-24",{"date":273,"type":21},"2030-10-24",{"name":275,"class":39},"University of California, San Francisco",{"id":277,"slug":278,"hasResults":12,"nctId":279,"briefTitle":280,"officialTitle":281,"acronym":282,"eligibilityCriteria":283,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":71,"enrollmentInfo":284,"targetDuration":4,"studyType":22,"phases":286,"briefSummary":287,"conditions":288,"keywords":290,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":293,"startDateStruct":295,"completionDateStruct":297,"leadSponsor":299,"locationsCount":40},"100647089","zepu-ai3-lower-limb-feedback-robot-training-study-100647089","NCT07705906","ZEPU-AI3 Lower Limb Feedback Robot Training Study","Safety, Efficacy and Feasibility of ZEPU-AI3 Lower Limb Feedback Training and Evaluation Robot","ZEPUAI3RCT","Inclusion Criteria:\n\n* • Lower-limb motor dysfunction from one of the following: (a) stroke (onset 2-24 months), (b) incomplete spinal-cord injury (neurological level T12 and below, ASIA C or D), (c) orthopedic surgery (e.g., knee\u002Fhip replacement) with persistent gait impairment \\> 3month post-surgery. Stroke onset between 2-24 months ensures inclusion of individuals in the subacute to chronic phase, where gait recovery is still achievable and measurable. Incomplete SCI targets individuals with partial motor preservation, who are capable of engaging in active gait training with robotic assistance.\n\n  * Age \\>18 and ≤ 60 years. This age limit is chosen because individuals with this age range generally have better cardiopulmonary reserve and musculoskeletal tolerance, allowing safer participation in intensive robotic-assisted training with reduced risk of adverse events. Excluding younger patients minimizes heterogeneity related to growth, neurodevelopmental factors and congenital disorders, which may influence gait mechanics and response to robotic therapy. Excluding older adults (\\>60 years) helps reduce confounding from age-related degenerative changes that may affect gait outcomes and safety.\n  * Able to provide informed consent and understand instructions which ensures participants can actively engage in therapy, follow safety instructions and report adverse events.\n  * Weight ≤ 100 kg (as per device spec) and height within device adjustable range (manufacturer spec). Exceeding weight or height limits may compromise mechanical support, safety, and accurate gait training.\n  * Medically stable and cleared by physician for exoskeleton use (no active infection, uncontrolled cardiac\u002Frespiratory disease, severe osteoporosis, uncontrolled epilepsy, untreated DVT) through pre-screening with necessary investigations.\n\nExclusion Criteria:\n\n* • Complete spinal cord injury with inability to bear any weight as it requires the patient to actively support some body weight or participate in stepping movements.\n\n  * Severe cognitive impairment (e.g., MMSE \\\u003C 24) preventing safe participation.\n  * Severe spasticity (Modified Ashworth Scale \\> 3) in lower limbs. High muscle tone or rigidity increases risk of joint strain, skin injury and falls during robotic-assisted training.\n  * Unstable fractures, severe hip\u002Fknee contractures (\\> 30° fixed flexion), severe osteoarthritis requiring imminent surgery. They can pose high risk for injury during weight-bearing or gait cycles.\n  * Uncontrolled cardiac arrhythmia, pacemaker incompatibility or implanted electronic device incompatible with robot sensors. Individuals with these conditions may face elevated risk of adverse cardiac events or device malfunction.\n  * Pregnancy as safety data for robotic exoskeleton use in pregnant individuals are lacking.",{"count":285,"type":21},32,[24],"Lower limb motor dysfunction resulting from stroke, spinal cord injury, or other neurological disorders substantially limits mobility, independence, and quality of life. Robotic rehabilitation has emerged as a promising approach to provide intensive, repetitive, task-oriented training. The ZEPU-AI3 Lower Limb Feedback Training and Evaluation Robot is designed to deliver interactive lower limb training while providing real-time performance feedback. This pilot randomized controlled trial aims to evaluate the safety, efficacy, and feasibility of ZEPU-AI3-assisted rehabilitation combined with conventional rehabilitation compared with conventional rehabilitation alone in patients with lower limb motor dysfunction. The primary outcomes include safety, feasibility, and changes in lower limb motor function, gait performance, and functional mobility. The findings will provide preliminary evidence to support future large-scale clinical trials and the implementation of robotic rehabilitation in clinical practice.",[139,27,289],"Gait Disorders",[144,149,291],"Feedback Training","2026-07-26",{"date":294,"type":32},"2026-07-28",{"date":296,"type":21},"2026-07-15",{"date":298,"type":21},"2026-11-15",{"name":159,"class":39},{"id":301,"slug":302,"hasResults":12,"nctId":303,"briefTitle":304,"officialTitle":305,"acronym":306,"eligibilityCriteria":307,"healthyVolunteers":308,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":309,"targetDuration":4,"studyType":22,"phases":311,"briefSummary":312,"conditions":313,"keywords":316,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":323,"lastUpdatePostDateStruct":324,"startDateStruct":326,"completionDateStruct":328,"leadSponsor":330,"locationsCount":331},"100600602","optimization-of-adaptive-rowing-seating-100600602","NCT07099625","Optimization of Adaptive Rowing Seating","Optimization of Adaptive Rowing Seating (OARS)","OARS","Inclusion Criteria:\n\n* Non-ventilator dependent paralysis, such as:\n\n  * central nervous system impairment\n  * spinal cord injuries with single neurological level in the cervical to lumbosacral region\n  * cerebrovascular accident with associated sequelae including but not limited to hemiparesis and spasticity\n  * neurodegenerative disorders including but not limited to amyotrophic lateral sclerosis, multiple sclerosis, multiple system atrophy, and parkinsonism\n* Poor trunk control\u002Fstability\n* Ability of body structure to fit within the limits of AIRS and the rowing system\n* Either volitional control of lower extremities or response\u002Ftolerance to electrical stimulation\n* Individuals who would be classified as PR2 or PR1 - FISA Para-Rowing Classifications\n\nExclusion Criteria:\n\n* Veterans will be excluded if they have:\n\n  * acute illness or injury\n  * active or recent pressure injuries in the last 6 months affecting their ability to safely row (e.g., the coccyx, ischial tuberosity, sacrum, etc.)\n* Individuals who would be classified as NE or PR3-PD - FISA Para-Rowing Classifications\n* Flap procedure to address pressure injury less than one year prior\n* Upper extremity pain that restricts rowing\n* Surgical procedure within past 6 months that would make the study procedures unsafe (e.g., tendon repairs\u002Ftransfers, neural decompressions, bony fusions, etc.)\n* Upper extremity or spine fractures within past 3 months, or longer if remains unstable\u002Fnot fully healed.\n* Medical conditions such as cardiovascular disease, pulmonary disease, or other conditions that would make the study procedures unsafe pregnancy\n* Inability to communicate with the study team in real time\n* Inability to follow simple commands\n* Unable or unwilling to give consent",true,{"count":310,"type":21},15,[24],"Adaptive sports programs are integral components to combating Veteran isolation, promoting wellbeing and seeking to build teams, networks, communities. These activity-based communities are medicine free treatment systems enhancing Veterans' health from a holistic perspective. This approach to Veteran healthcare is critical as studies indicate Veterans not only have 56% higher perceived social isolation but are also 1.5x more susceptible to suicide than the general public. It is imperative to improve access to exercise and physical activity through adaptive sport or recreation. This proposal is going to focus on Adaptive Indoor Rowing for Veterans with limited or changing trunk stability (i.e. SCI\u002FD, paralysis, paresis, etc.). Rowing is a unique full-body activity that increases cardiovascular demand and increases coordination and aerobic capacity through movement. This proposal aims to address critical gaps in adaptive rowing technology and provide Veterans with limited trunk stability access to full stroke adaptive rowing.",[184,27,314,315],"Neurodegenerative Disorders","Cerebrovascular Accident With Associated Sequelae",[317,318,319,320,321,322],"Veteran Health","Sports for Persons with Disabilities","Paralysis","Paresis","Adaptive Sports","Indoor Rowing","2026-07-22",{"date":325,"type":32},"2026-07-24",{"date":327,"type":21},"2026-10-05",{"date":329,"type":21},"2028-12-31",{"name":125,"class":126},2,{"id":333,"slug":334,"hasResults":12,"nctId":335,"briefTitle":336,"officialTitle":336,"acronym":4,"eligibilityCriteria":337,"healthyVolunteers":12,"sex":17,"minAge":338,"maxAge":71,"enrollmentInfo":339,"targetDuration":4,"studyType":22,"phases":341,"briefSummary":342,"conditions":343,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":344,"lastUpdatePostDateStruct":345,"startDateStruct":346,"completionDateStruct":348,"leadSponsor":350,"locationsCount":40},"100551057","epidural-electrical-stimulation-for-spinal-cord-injury-patients-and-corticospinal-motor-circuit-improvement-100551057","NCT06455137","Epidural Electrical Stimulation for Spinal Cord Injury Patients and Corticospinal Motor Circuit Improvement","Inclusion Criteria:\n\n* SCI ASIA: A, B, C,D\n* Between 20 and 70 year of age\n* \\>1 year post SCI\n* Complete or incomplete spinal cord injury.\n* Expected will undergo spinal cord stimulation surgery.\n* Continued rehabilitation after surgery for spinal cord injury.\n* Able to comply with procedures and follow up.\n* Stable medical condition without cardiopulmonary disease or dysautonomia that would - contraindicate participation in lower extremity rehabilitation or testing activities\n\nExclusion Criteria:\n\n* Have significant cognitive impairment (MMSE\\\u003C24).\n* Had a mental illness within one year or been treated in the past.\n* Have Major depressive disorder.\n* Active cancer diagnosis.\n* Painful musculoskeletal dysfunction, unhealed fracture, contracture, pressure sore, or urinary tract infection that might interfere with stand or step training.\n* Cardiovascular or musculoskeletal disease or injury that would prevent full participation in physical therapy intervention.\n* Unable to read and\u002For comprehend the consent form.\n* Have concerns about this trial and do not sign consent.","20 Years",{"count":340,"type":21},20,[24],"The study aims to examine the plausible interventional mechanisms underlying the effects of epidural spinal cord stimulation.",[27],"2026-07-21",{"date":323,"type":32},{"date":347,"type":32},"2024-04-30",{"date":349,"type":21},"2029-12-31",{"name":351,"class":39},"Buddhist Tzu Chi General Hospital",{"id":353,"slug":354,"hasResults":12,"nctId":355,"briefTitle":356,"officialTitle":357,"acronym":4,"eligibilityCriteria":358,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":359,"targetDuration":4,"studyType":22,"phases":360,"briefSummary":361,"conditions":362,"keywords":363,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":368,"startDateStruct":370,"completionDateStruct":372,"leadSponsor":374,"locationsCount":40},"100610012","spinal-neurorehabilitation-for-veterans-with-sci-100610012","NCT07222046","Spinal Neurorehabilitation for Veterans With SCI","Identifying Residual Connectivity in Veterans With Spinal Cord Injury for Precision Neurorehabilitation","Inclusion Criteria:\n\n* All participants must be able to independently read and understand study information materials necessary to ensure informed consent.\n* All participants must have a chronic spinal cord injury occurring \\>1 year prior to study enrollment.\n* Ability to follow simple commands in English.\n\nExclusion Criteria:\n\n* Contraindications to the use of external magnetic or electrical stimulation (e.g., epilepsy, intracranial metal, implanted electrosensitive device, etc.)\n* Significant neurological comorbidities that may affect neurophysiological recordings\n* Functional disability prior to spinal cord injury\n* Visual or auditory disorders limiting ability to participate in study procedures\n* Pregnancy\n* Primary psychiatric disorders or dissociative mental symptoms that impair informed consent\n* Significant chronic pain that may preclude an MRI scan or performing neurorehabilitation exercises\n* Frequent and significant spasticity that may preclude an MRI scan or neurorehabilitation exercises.",{"count":49,"type":21},[24],"Chronic spinal cord injury (SCI) is a debilitating disorder in Veterans and the broader U.S. population that does not have a cure. Veterans with severe SCI demonstrate permanent loss of sensory and motor function below their injury resulting in decreased quality of life and independence. Recently, electrical spinal neuromodulation has emerged as a potential approach to restore voluntary motor function and locomotion in persons with chronic SCI. However, spinal neuromodulation has yet to translate to clinical use due to small sample sizes in research studies and a lack of information on which patients would benefit. Here, the investigators propose a novel approach to evaluate the priorities and barriers faced by Veterans with SCI to use spinal neuromodulation, understand the neural connections remaining in Veterans with severe SCI, and determine potential functional improvements using non-invasive spinal neuromodulation technology. This research represents the first step towards deploying techniques that could dramatically improve function and quality of life for Veterans with SCI.",[27],[364,365,366,367,149],"Spinal neuromodulation","Transcutaneous stimulation","Spinal cord stimulation","Neuroanatomy",{"date":369,"type":32},"2026-07-17",{"date":371,"type":21},"2026-09-01",{"date":373,"type":21},"2031-06-30",{"name":125,"class":126},{"id":376,"slug":377,"hasResults":12,"nctId":378,"briefTitle":379,"officialTitle":380,"acronym":4,"eligibilityCriteria":381,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":252,"enrollmentInfo":382,"targetDuration":4,"studyType":22,"phases":384,"briefSummary":385,"conditions":386,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":387,"lastUpdatePostDateStruct":388,"startDateStruct":389,"completionDateStruct":391,"leadSponsor":393,"locationsCount":40},"100647104","combined-magnetic-stimulation-and-ultrasound-for-detrusor-overactivity-in-sci-100647104","NCT07704268","Combined Magnetic Stimulation and Ultrasound for Detrusor Overactivity in SCI","A Randomized, Double-Blind, Sham-Controlled Trial of Sacral Nerve Root High-Frequency Magnetic Stimulation Combined With Ultrasound Therapy for Detrusor Overactivity in Patients With Spinal Cord Injury","Inclusion Criteria:\n\n1. Diagnosis of spinal cord injury (SCI) above the sacral level according to the International Standards for Neurological Classification of Spinal Cord Injury (revised 2011), confirmed by CT or MRI;\n2. Detrusor overactivity confirmed by urodynamic study;\n3. No severe urinary system diseases such as tumors, stones, infection, or organic urinary tract obstruction;\n4. No severe hepatic\u002Frenal insufficiency, pulmonary, or cardiovascular diseases;\n5. Aged 18-80 years;\n6. Able to understand and comply with the required examinations, rehabilitation assessments, and treatment, and provide written informed consent.\n\nExclusion Criteria:\n\n1. Unstable vital signs or critically ill condition;\n2. Severe autonomic dysreflexia;\n3. Presence of metallic implants within 10 cm of the magnetic stimulation treatment area;\n4. Any other diseases or conditions that may interfere with the study outcomes.",{"count":383,"type":21},44,[24],"This clinical trial aims to investigate whether the combination of high-frequency sacral nerve root magnetic stimulation and bladder-directed ultrasound therapy can effectively improve detrusor overactivity (involuntary bladder contractions) and related voiding dysfunctions in patients with spinal cord injury. The main questions it seeks to answer are:\n\nWhat is the effect of high-frequency sacral nerve root magnetic stimulation on detrusor overactivity and bladder function in patients with spinal cord injury?\n\nWhat is the effect of bladder-directed ultrasound therapy on detrusor overactivity and bladder wall compliance in patients with spinal cord injury?\n\nIs the combination of these two treatment modalities superior to magnetic stimulation alone?",[27],"2026-07-09",{"date":296,"type":32},{"date":390,"type":21},"2026-07-10",{"date":392,"type":21},"2027-04-30",{"name":394,"class":39},"Shengjing Hospital",{"id":396,"slug":397,"hasResults":12,"nctId":398,"briefTitle":399,"officialTitle":400,"acronym":4,"eligibilityCriteria":401,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":402,"targetDuration":4,"studyType":22,"phases":403,"briefSummary":405,"conditions":406,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":387,"lastUpdatePostDateStruct":411,"startDateStruct":412,"completionDateStruct":414,"leadSponsor":416,"locationsCount":40},"100549778","phase-1-novel-soluble-epoxide-hydrolase-inhibitor-for-neuropathic-pain-in-patients-with-spinal-cord-injury-100549778","NCT06438471","Novel Soluble Epoxide Hydrolase Inhibitor for Neuropathic Pain in Patients With Spinal Cord Injury","Development of a Novel Soluble Epoxide Hydrolase Inhibitor as a Strategy for Treating Neuropathic Pain in Patients With SCI","Inclusion Criteria:\n\nEach subject must meet all of the following criteria to be enrolled in this study:\n\n1. Male and female subjects must be 18 and older.\n2. Subjects must be willing to provide written informed consent to participate in the study.\n3. Subjects must be able to provide own transportation to study site every day for the duration of the study.\n4. Subjects with either a traumatic or a non-traumatic SCI may be eligible to enroll in this study. For subjects with complete or incomplete traumatic spinal cord injuries (tSCI), or complete non-traumatic spinal cord injury: Subjects must have a complete or incomplete T6 or below tSCI, or complete non-traumatic SCI of at least 12 months duration, with below-level neuropathic pain identified by the International Spinal Cord Injury Pain (ISCIP) classification criteria. Importantly, subjects must not be ventilator-dependent as detailed in Exclusion Criteria 1. For subjects with degenerative partial spinal cord injuries (pSCI): Subjects must have an incomplete, non-traumatic, SCI at any level secondary to degenerative spinal disorders such as disc degeneration, spinal stenosis, or spondylosis, with associated chronic neuropathic pain. The injury and the associated pain must be of at least 12 months duration. Neuropathic pain should meet the ISCIP classification criteria. Importantly, subjects must not be ventilator-dependent as detailed in Exclusion Criteria 1.\n5. Subjects must have completed a minimum of 6 of the 7 daily assessments for average and worst daily pain prior to final screening, using an 11-point numerical rating scale (NRS) for average daily pain intensity, and the arithmetic average daily SCI neuropathic pain score must be ≥4 and ≤9, with a standard deviation less than or equal to 1.2. Daily pain assessment screenings will be done over the phone with the study coordinator after informed consent is obtained.\n6. Subjects must have failed at least 2 classes of medications for their neuropathic pain due to SCI (classes may include antidepressants, antiepileptics, opioids, anti-inflammatories, topical treatments, etc.).\n7. Subjects must be in overall stable condition, as determined by pre-study medical history, physical examination, clinical laboratory tests, and 12 lead ECG measurements\n8. Subjects must have normal or not clinically significant clinical laboratory test results, as determined by the study investigator, including coagulation panel, blood cell counts, comprehensive metabolic panel analytes, and creatinine clearance (60 cm3\u002Fmin or greater). Clinical laboratory tests results that are consistent with known, stable comorbidities will be allowed as long as the comorbidities do not represent an exclusion criteria per se.\n9. Subjects must have a negative screening for HIV, Hepatitis C, and Hepatitis B within 30 days of randomization.\n10. Subjects must have a normal hypothalamic-pituitary-adrenal and hypothalamic-pituitary-gonadal axes screening study.\n11. Subjects must have a negative urinary drug screen (UDS) for illicit drugs (marihuana\u002FTHC are allowed) and serum ethanol level \\\u003C80 mg\u002FdL.\n12. Male subjects who are not surgically sterile (vasectomized) and their female sexual partners must agree to use contraception during the study period and for 2 months afterward.\n13. Male subjects must not donate sperm during the study and for 12 months after receiving the last dose of study drug.\n14. Female subjects must be non-pregnant, non-lactating, and either postmenopausal for at least 1 year, or surgically sterile (bilateral tubal ligation ('clipping or tying tubes' or hysterectomy) for at least 3 months, or they must agree to use two forms of highly effective contraception method (less than 1 pregnancy per 100 people using the method for one year), from 28 days and\u002For their last confirmed menstrual period prior to study enrollment (whichever is longer) until 2 months after clinic discharge. Postmenopausal status will be defined as follow: minimum 1 year; amenorrhea duration of 12 consecutive months and a serum FSH value \\>40 IU\u002FL; postmenopausal status must be confirmed by an FSH test at Screening). Highly effective contraception methods include: Intra-uterine device (IUD) containing either copper or levonorgestrel (e.g., Mirena®), and\u002For barrier methods of contraception, including condoms (external or internal) and diaphragm ('cap'). Hormonal methods of contraception (with the exception of hormonal IUD) are not permitted within this study. Female participants will refrain from using hormonal contraceptives for at least 28 days prior to study entry until the end of the study period. Participants\u002FParticipant's partner(s) must also use a barrier form of contraception, from the first dose of study drug through until 2 months after the last dose. For all females of childbearing potential, the pregnancy test result must be negative at Screening and Pre-Study Baseline (Day -1).\n15. Subjects must be able to speak, read, and understand English sufficiently to allow comprehension and completion of all study assessments.\n\nExclusion Criteria:\n\nSubjects meeting any of the following criteria will be excluded from the study:\n\n1. Ventilator-dependent subjects, with the exception of nocturnal use of CPAP or BiPAP.\n2. Subjects with pain that is not present every day (chronic) or where the pain description does not have a classic neuropathic phenotype.\n3. Subjects with other chronic neuropathic pain conditions, including painful diabetic neuropathy, HIV-associated neuropathic pain, chemotherapy or ethanol-associated neuropathy.\n4. Subjects with other pain syndromes that may confound assessment or self-evaluation of the SCI neuropathic pain.\n5. Subjects with only negative symptoms, defined as numbness without clear evidence of spontaneous pain, either constant or episodic.\n6. Non-opioid pain medications will be allowed if at a fixed stable dose for more than 1 month prior to Screening with no anticipation of the dose changing during the study, and if they do not interfere with the subject's ability to rate pain as per Investigator's discretion. Allowed non-opioid medications include gabapentin, pregabalin, duloxetine, acetaminophen, ibuprofen, celecoxib, meloxicam, other antidepressants including amitriptyline and other antiepileptics, as well as topical capsaicin and topical lidocaine.\n7. Subjects using opioid medications will be required to be on a dose of 60 morphine milligrams equivalents (MME) per day or less, and with a stable dose for at least four (4) weeks prior to consent, with no anticipation of dose changing during the study.\n8. Subjects with active Hepatitis A, Hepatitis B and\u002For Hepatitis C.\n9. Subjects with any clinically unstable or significant cardiovascular (including acute coronary syndrome within the prior year to Screening), renal, hepatic, respiratory, gastrointestinal, hematological, endocrine, or infectious disease (including HIV infection).\n10. Subjects with clinically significant abnormalities on screening vital signs, laboratory tests, and\u002For ECG. Subjects with poor venous access will also be excluded.\n11. Subjects with a history of disorders of the hypothalamic-pituitary-adrenal axis, including adrenal insufficiency and Cushing's, or with a history of disorders of the hypothalamic-pituitary-gonadal axis, including hypogonadism.\n12. Subjects who have used any topical, oral, or intravenous exogenous corticosteroids within 12 weeks and\u002For intra-articular exogenous corticosteroids within 6 months prior to the start of the trial, or who plan on using them during the study.\n13. Subjects who have used fludrocortisone or exogenous testosterone products within 12 weeks prior to the start of the trial or who plan on using them during the study.\n14. Subjects who have used (within 14 of randomization) or plan on using during the duration of the study any renin-angiotensin system (RAS)-acting drugs (including angiotensin-receptor blockers, or ARBs; angiotensin-converting enzyme inhibitors, or ACE-inhibitors; and direct renin inhibitors) or mineralocorticoid receptor antagonists (such as spironolactone and eplerenone)\n15. Subjects who have used chemotherapy agents, or who have a personal history of cancer or cancer in first degree relatives suggestive of elevated cancer risk, other than nonmetastatic skin cancer that has been completely excised, within 5 years prior to Screening.\n16. Subjects with a history of bacterial, fungal, or viral infection requiring treatment with antibiotics, antifungal agents, or antivirals within 1 month prior to randomization.\n17. Subjects who have used (within 14 days of randomization) or plan on using during the duration of the study any prescription or over-the-counter drugs that are moderate-strong CYP3A4 inducers or inhibitors.\n18. Subjects who have used (within 14 days of randomization) or plan on using during the duration of the study any dietary aids, supplements, or foods that are moderate-strong CYP3A4 inhibitors (e.g., grapefruit juice).\n19. Subjects with difficulty in swallowing oral medications.\n20. Subjects with serious psychosocial comorbidities as determined by the Investigator.\n21. Subjects with current cognitive or major psychiatric disorders, or any other condition that could interfere with compliance with study procedures.\n22. Subjects with a positive drug or alcohol test (\\>80 mg\u002FdL) during Screening and\u002For admission (a positive THC test will be allowed as long as it consists of minimal social use, per discretion of Investigator), or with a recent history of binge drinking within 1 week of randomization.\n23. Subjects who have used any other investigational drug within 1 month prior to enrollment. If the investigational drug is known to have a long half-life, a longer washout period will be done.\n24. Subjects with a presence or history of active gastrointestinal disorder, including esophageal or gastroduodenal ulceration, or renal, hepatic, or coagulant disorder within 1 month prior to enrollment.\n25. Subjects with a family history of significant cardiac disease (i.e., sudden death in first degree relative; myocardial infarction before the age of 50).\n26. Subjects with confirmed COVID-19, or suspected COVID-19 (e.g., developed symptoms of a respiratory infection such as cough, sore throat, shortness of breath, or fever, but did not get tested for COVID 19) within 30 days of randomization.\n27. Subjects who have received a COVID-19 vaccine within 30 days of randomization or are planning on receiving it during the study duration.\n28. Exclude subjects with spinal cord injury at T6 or higher with a history of neurogenic bladder.\n29. Exclude subjects with documented autonomic dysreflexia (AD) or a history of episodes consistent with undiagnosed AD as determined by an experienced clinician.",{"count":135,"type":21},[404],"PHASE1","The goal of this clinical trial is to evaluate safety and tolerability of multiple oral doses of EC5026 in male and female patients with neuropathic pain due to traumatic or non-traumatic (degenerative) spinal cord injury. The main question it aims to answer is whether EC5026 is safe and well tolerated in SCI patients with neuropathic pain. In addition, this trial will also study the effects of EC5026 on pain.\n\nResearchers will compare EC5026 to placebo.\n\nParticipants will be asked to:\n\n* Take EC5026 or placebo in a masked fashion, once daily, for 14 consecutive days.\n* Undergo physical exams, vital signs assessments, ECGs, and blood draws\n* Complete assessments of pain, sleep, functional status, and perception of change",[27,407,408,409,410],"Neuropathic Pain","Degenerative Disc Disease","Spinal Stenosis","Spondylosis",{"date":390,"type":32},{"date":413,"type":32},"2026-05-01",{"date":415,"type":21},"2027-12",{"name":417,"class":418},"EicOsis Human Health Inc.","INDUSTRY",{"id":420,"slug":421,"hasResults":12,"nctId":422,"briefTitle":423,"officialTitle":424,"acronym":425,"eligibilityCriteria":426,"healthyVolunteers":12,"sex":17,"minAge":70,"maxAge":427,"enrollmentInfo":428,"targetDuration":4,"studyType":22,"phases":430,"briefSummary":431,"conditions":432,"keywords":435,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":439,"lastUpdatePostDateStruct":440,"startDateStruct":441,"completionDateStruct":443,"leadSponsor":445,"locationsCount":331},"100104456","evaluation-of-an-advanced-lower-extremity-neuroprostheses-100104456","NCT00623389","Evaluation of an Advanced Lower Extremity Neuroprostheses","Evaluation of Advanced Lower Extremity Neuroprostheses","LE-IST","Phase I Inclusion Criteria\n\n1. Skeletal maturity and ability to sign informed consent (\\>18 years)\n2. Non-ventilator dependent paralysis resulting from injuries such as: mid cervical\u002Fthoracic (C4 or below) spinal cord injuries, poststroke hemiparesis, TBI, or MS, affecting the trunk and\u002For lower limbs\n3. Innervated and excitable lower extremity and trunk musculature\n4. Adequate social support and stability\n5. Willingness to comply with follow-up procedures\n\nPhase I Exclusion Criteria\n\n1. Non-English speaking\n2. Females who are pregnant\n3. Current pressure injuries that would be exacerbated by study activities\n4. Severe contractures or uncontrolled spasticity of any major joint of the upper or lower extremities that results in a fixed deformity that would interfere with study activities\n5. History of spontaneous fractures or other evidence of excessively low bone density\n6. History of vestibular dysfunction, balance problems, or spontaneous falls\n7. Acute and or\u002Funtreated orthopedic problems that would prevent a participant from weight bearing or exercising such as a dislocation or fracture.","75 Years",{"count":429,"type":21},10,[24],"The purpose of this study is to evaluate a surgically implanted functional electrical stimulation (FES) system to facilitate exercise, standing, stepping and\u002For balance in people with various degrees of paralysis.",[27,139,319,433,434],"Tetraplegia","Paraplegia",[436,437,438,139,434,433],"Neurologic disorders","Rare disease","Spinal cord injuries","2026-07-08",{"date":390,"type":32},{"date":442,"type":32},"2018-06-01",{"date":444,"type":21},"2027-12-31",{"name":446,"class":39},"Case Western Reserve University",{"id":448,"slug":449,"hasResults":12,"nctId":450,"briefTitle":451,"officialTitle":452,"acronym":453,"eligibilityCriteria":454,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":455,"targetDuration":4,"studyType":22,"phases":457,"briefSummary":458,"conditions":459,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":461,"lastUpdatePostDateStruct":462,"startDateStruct":463,"completionDateStruct":465,"leadSponsor":467,"locationsCount":40},"100463924","wrist-extensor-mep-up-conditioning-for-individuals-with-incomplete-spinal-cord-injury-100463924","NCT05321017","Wrist Extensor MEP Up-conditioning for Individuals With Incomplete Spinal Cord Injury","Can Increasing Motor Evoked Potential Size Improve Upper Extremity Motor Function in Individuals With Incomplete Spinal Cord Injury?","uMEP","Inclusion Criteria:\n\n1. a history of injury to spinal cord at or above C6\n2. neurologically stable (\\>6 mo post SCI)\n3. medical clearance to participate\n4. weak wrist extension at least unilaterally\n5. expectation that current medication will be maintained without change for at least 3 months. Stable use of anti-spasticity medication (e.g., baclofen, diazepam, tizanidine) is accepted. In participants with bilateral wrist extension weakness, the more severely impaired arm is studied.\n\nExclusion Criteria:\n\n1. motoneuron injury\n2. medically unstable condition\n3. cognitive impairment\n4. a history of epileptic seizures\n5. metal implants in the cranium\n6. implanted biomedical device in or above the chest (e.g., a cardiac pacemaker, cochlear implant)\n7. no measurable MEP elicited in the ECR\n8. unable to produce any voluntary ECR EMG activity\n9. extensive use of functional electrical stimulation to the arm on a daily basis\n10. pregnancy (due to changes in posture and potential medical instability).",{"count":456,"type":21},5,[24],"The purpose of this study is to examine the relationship between common clinical assessments and measurements of the function of brain-spinal cord-muscle connections, and to examine the effects of training a brain-spinal cord-muscle response in individuals with incomplete spinal cord injury. A transcranial magnetic stimulator (TMS) is used for examining brain-to-muscle pathways. This stimulator produces a magnetic field for a very short period of time and indirectly stimulates brain cells with little or no discomfort. The target muscle is the wrist extensor (extensor carpi radialis) muscle that bends the wrist back. It is hypothesized that training the wrist extensor muscle response to transcranial magnetic stimulation will increase the strength of the brain-to-muscle pathway, which will improve the ability to move the arm.\n\nIt is hoped that the results of this training study will help in developing therapy strategies for individuals, promoting better understanding of clinical assessments, and understanding treatments that aim to improve function recovery in people with spinal cord injury (SCI).\n\nThis study requires 30 visits, and each visit will last approximately 1.5 hours.",[27,460],"Quadriplegia","2026-07-07",{"date":439,"type":32},{"date":464,"type":32},"2021-10-12",{"date":466,"type":21},"2027-06-30",{"name":468,"class":39},"Medical University of South Carolina",{"id":470,"slug":471,"hasResults":12,"nctId":472,"briefTitle":473,"officialTitle":474,"acronym":4,"eligibilityCriteria":475,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":476,"targetDuration":4,"studyType":22,"phases":478,"briefSummary":479,"conditions":480,"keywords":481,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":487,"lastUpdatePostDateStruct":488,"startDateStruct":490,"completionDateStruct":492,"leadSponsor":494,"locationsCount":40},"100606126","efficacy-of-a-wearable-noninvasive-neuromodulation-device-100606126","NCT07171489","Efficacy of a Wearable Noninvasive Neuromodulation Device","An Early Feasibility Study of Using the AccelBand, a Leg-worn Transcutaneous Neuromodulation (TNM) Device, for Neurogenic Bowel Dysfunction (NBD) in People With Spinal Cord Injury (SCI)","Inclusion Criteria:\n\n* Traumatic or non-traumatic spinal cord injury (SCI)\n* SCI level above the twelfth thoracic vertebra (T12)\n* SCI classified as Sensory Incomplete (AIS B), C, or D\n* Post-SCI time ≥ 6 months;\n* Neurogenic bowel dysfunction (NBD) as a result of SCI\n* Willing to sign the informed consent form\n\nExclusion Criteria:\n\n* Significant cognitive impairment, impeding the ability to provide informed consent or complete the questionnaire\n* Prior gastrointestinal surgeries other than uncomplicated appendectomies, cholecystectomy or cesarean sections\n* Known diagnosis of diabetes mellitus\n* Known current or past severe significant psychiatric disorder\n* Known current substance abuse\n* Implanted medical devices for electrical stimulation (e.g. cardiac pacemaker)\n* Taking opioid medications on a regular daily basis\n* Currently pregnant or actively planning a pregnancy\n* Active inflammatory bowel disease\n* Ventilator dependency\n* Severe autonomic dysreflexia\n* No preservation of the sacral spinal reflexes: bulbocavernosus, patella, or Achilles\n* Complete absence of sensation in the leg (since it is needed for calibrating the TNM intensity)",{"count":477,"type":21},100,[24],"The aim of this study is to investigate the potential of transcutaneous neuromodulation (TNM) to treat slow colonic transit and constipation, termed the Neurogenic bowel dysfunction (NBD), in people with SCI. In this project, the study team will investigate the impact of an active treatment intervention vs. a sham control intervention on NBD symptoms in patients with SCI.\n\nThe study hypotheses:\n\n* The proposed TNM treatment at a leg point will reduce NBD symptoms between baseline and post-therapy, when compared to the sham-TNM treatment.\n* The therapeutic effect of TNM to improve the NBD symptoms is associated with improvement of the autonomic function in SCI patients.",[27],[482,483,484,485,486],"Neurogenic bowel dysfunction","Transcutaneous neuromodulation","Questionnaires","AccelBand","Anorectal manometry test","2026-07-01",{"date":489,"type":32},"2026-07-06",{"date":491,"type":21},"2026-07",{"date":493,"type":21},"2029-11",{"name":495,"class":39},"University of Michigan",{"id":497,"slug":498,"hasResults":12,"nctId":499,"briefTitle":500,"officialTitle":501,"acronym":502,"eligibilityCriteria":503,"healthyVolunteers":12,"sex":17,"minAge":504,"maxAge":427,"enrollmentInfo":505,"targetDuration":4,"studyType":22,"phases":507,"briefSummary":508,"conditions":509,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":487,"lastUpdatePostDateStruct":510,"startDateStruct":511,"completionDateStruct":513,"leadSponsor":515,"locationsCount":331},"100529673","promoting-recovery-outcomes-through-precise-early-locomotor-interventions-in-persons-with-spinal-cord-injury-100529673","NCT06176833","Promoting Recovery Outcomes Through Precise Early Locomotor Interventions in Persons With Spinal Cord Injury","Critical Time Window for Rehabilitation After Incomplete Spinal Cord Injury: Early vs Late Locomotor Training","PROPEL-SCI","Inclusion Criteria:\n\n* History of Acute and Traumatic SCI with AIS classification of B, C, or D between the neurological levels of C5 and T12\n* Between the ages of 16-74\n* Weight bearing as tolerated in bilateral lower extremities\n* Able to tolerate a harness\n* Ability to provide informed consent. For minors, consent of parents or primary caregivers\u002Fguardians and assent of the minor\n* Able to provide informed consent within 60 days of injury onset\n* Able to participate in all study related activities, including 1-year follow up\n\nExclusion Criteria:\n\n* Orthopedic injuries, fractures, surgeries, or other conditions affecting locomotor function or weight bearing\n* A weight over 250lbs and if so a BMI greater than 30, or deemed clinically inappropriate due to body habitus\n* Moderate to sever traumatic brain injury of other neurological conditions at a severity which impairs cognition\n* Presence of uncontrolled orthostatic hypotension that limits active participation in intense physical rehabilitation program.\n* Other medical complications such as severe heart failure or large\u002Fdeep pelvic or lower abdominal wounds that may limit the ability to safely don and doff a harness for ambulation\n* Pregnancy, as confirmed by blood draw","16 Years",{"count":506,"type":21},108,[24],"The purpose of this study is to evaluate if a specific type of additional walking therapy, called body weight supported treadmill training (BWSTT) affects walking ability following a traumatic spinal cord injury. Specifically, the study will look at whether starting BWSTT, which uses a body harness to support body weight while walking on a treadmill at different times within the first 6 months after the injury, makes a difference in how effective this therapy may be, While we know that the brain re-learns patterns following an injury, there has not been a lot of prior research evaluating how starting this type of walking therapy at specific times within the first 6 months after injury may impact any effectiveness of the additional therapy.\n\nThe study will randomize participants into four groups: those who start this therapy within 60 days, within 3 months, within 6 months or who do not receive this additional research therapy. Randomization means that which group you will be in as part of this study is determined by chance, like the flip of a coin. The additional walking therapy for this research study, if you are randomized for one of the three groups who receives the additional therapy, will be given on top of (meaning in addition to) any standard of care therapies that you may be receiving at that time point after your injury.",[27],{"date":489,"type":32},{"date":512,"type":32},"2024-03-21",{"date":514,"type":21},"2029-12",{"name":516,"class":39},"Milap Sandhu",{"id":518,"slug":519,"hasResults":12,"nctId":520,"briefTitle":521,"officialTitle":521,"acronym":522,"eligibilityCriteria":523,"healthyVolunteers":12,"sex":17,"minAge":504,"maxAge":4,"enrollmentInfo":524,"targetDuration":4,"studyType":22,"phases":526,"briefSummary":527,"conditions":528,"keywords":529,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":487,"lastUpdatePostDateStruct":531,"startDateStruct":532,"completionDateStruct":534,"leadSponsor":535,"locationsCount":537},"100434399","duroplasty-for-injured-cervical-spinal-cord-with-uncontrolled-swelling-100434399","NCT04936620","Duroplasty for Injured Cervical Spinal Cord With Uncontrolled Swelling","DISCUS","Inclusion Criteria:\n\n1. Age ≥16 years\n2. Severe cervical (C2 - T1) traumatic spinal cord injury (AIS grade A-C)\n3. Deemed to require and be suitable for surgery that includes laminectomy by local surgeon\n4. Surgery within 72 hours of traumatic spinal cord injury\n5. Able to provide informed consent or consultee declaration or proxy consent.\n\nExclusion Criteria:\n\n1. Dural tear due to traumatic spinal cord injury\n2. Life-limiting or rehabilitation-restricting co-morbidities\n3. Thoracic or lumbar traumatic spinal cord injury\n4. Other central nervous system disease",{"count":525,"type":21},222,[24],"QUESTION. Does duroplasty improve outcome after spinal cord injury?\n\nWHAT DO WE STUDY? We will investigate whether performing a surgical procedure called duroplasty improves outcomes after spinal cord injury.\n\nWHY SPINAL CORD INJURY? Spinal cord injury is a devastating condition that causes permanent disability such as paralysis, numbness and loss of bladder and bowel control. Currently, there are no treatments shown to improve outcome after spinal cord injury.\n\nWHAT IS DUROPLASTY? Duroplasty is an operation that involves opening the tough membrane around the cord, called the dura, and stitching a patch of artificial dura to expand the space around the swollen cord.\n\nWHY IS DUROPLASTY BEING STUDIED? Based on our preliminary evidence, we think that the dura causes cord pressure after injury. We have shown in a small study of patients that performing this operation safely and effectively reduces pressure on the injured cord.\n\nWHO IS ELIGIBLE? Adult patients with severe spinal cord injuries in the neck who will have surgery within 72 hours.\n\nWHAT TREATMENT? Those who agree to take part will be allocated by chance (like tossing a coin) to standard treatment or standard treatment plus duroplasty. Some patients will also be asked to take part in a smaller study that involves placing probes at the injury site.\n\nWHERE? Initially, we will recruit patients from U.K. Major Trauma Centres. Most assessments will be done in U.K. Spinal Injury Centres. Later on, we we also started recruiting from overseas.\n\nHOW LONG? We aim to recruit 222 - 260 patients over 4 years. Patients will be followed up for a year.\n\nWHAT DO WE ASSESS? Patients will be assessed (using questionnaires and by examination) how well they can use their hands, walk, control their bladder and bowel and their quality of life. Some of these assessments will be repeated at 3, 6 and 12 months after surgery.\n\nWHAT IS THE OPTIONAL MECHANISTIC STUDY? DISCUS includes an optional study for at least 50 patients who will take part in the randomised controlled trial. The aim of the mechanistic study is to determine how duroplasty improves outcome, i.e. whether duroplasty reduces cord compression, improves blood flow to the injured cord perfusion, improves cord metabolism and reduces cord inflammation.\n\nWHAT IS THE OPTIONAL INFORMATION STUDY? For the first two years, a study called QuinteT Recruitment Intervention (QRI) is designed to optimise patient recruitment and informed consent in the trauma setting.",[27],[530],"Decompression, surgical; Neurosurgery; Paralysis",{"date":489,"type":32},{"date":533,"type":32},"2021-10-08",{"date":82,"type":21},{"name":536,"class":39},"St George's, University of London",34,{"id":539,"slug":540,"hasResults":12,"nctId":541,"briefTitle":542,"officialTitle":543,"acronym":4,"eligibilityCriteria":544,"healthyVolunteers":12,"sex":17,"minAge":70,"maxAge":71,"enrollmentInfo":545,"targetDuration":4,"studyType":22,"phases":546,"briefSummary":547,"conditions":548,"keywords":549,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":551,"lastUpdatePostDateStruct":552,"startDateStruct":554,"completionDateStruct":556,"leadSponsor":558,"locationsCount":40},"100642177","hybrid-hiit-fes-cycling-program-on-individuals-with-spinal-cord-injury-to-improve-health-100642177","NCT07648173","Hybrid HIIT-FES Cycling Program on Individuals With Spinal Cord Injury to Improve Health","The Effects of a Hybrid HIIT-FES Cycling Program on Individuals With Spinal Cord Injury to Improve Cardiovascular and Metabolic Health","Inclusion Criteria:\n\n* men and women ages 21-70 years\n* C4-T12 SCI American Spinal Injury Association Impairment Scale A, B, and C as per International Standards for Neurological Classification of SCI\n* ≥1 years post-SCI\n* Participants must be able to perform voluntary arm cycling.\n\nExclusion Criteria:\n\n* pressure wounds on buttocks or feet\n* unhealed bone fractures or history of fragility fractures\n* uncontrolled cardiovascular disease\n* uncontrolled Type-2 diabetes\n* severe osteoporosis (T score below -4)\n* uncontrolled autonomic dysreflexia\n* orthopedic or other problems that preclude leg and arm cycling.",{"count":93,"type":21},[24],"Project Summary\u002FAbstract Obesity and metabolic syndrome (obesity, dyslipidemia, hyperglycemia, hypertension) are epidemic in the spinal cord injured (SCI) population. A recent study assessing the body composition and metabolic syndrome rates of 72 motor complete chronic SCI individuals revealed an obesity rate of over 90% and a metabolic syndrome rate of 60%. These results are significantly higher than in the general population. As such individuals with SCI typically have systemic inflammation and an accelerated trajectory towards cardiometabolic disease, and early mortality. Although the accelerated trajectory is multi-factorial, substantial evidence implicates sedentary behavior and low physical activity levels as significant contributing factors. Exercise strategies for individuals with SCI have included upper body arm crank exercise (ACE), functional electrical stimulation leg cycling exercise (FES-LCE), or a combination of the two (FES Hybrid Exercise). These modalities have yielded modest improvements in physical fitness and cardiometabolic risk profiles in individuals with SCI. FES-LCE reportedly increased lean-to-fat mass ratio, enhanced peripheral blood flow and vasoreactivity, and increased bone mass in the paralyzed legs. In addition, FES-LCE improves metabolic function as evidenced by increased glucose disposal. There is evidence that high-intensity interval training exercise can increase muscle mass and improve cardiovascular fitness with considerably less time commitment than non-interval activities. However, given many individuals with SCI respond poorly to the onset of training a primer exercise program for the extremely deconditioned muscles is recommended for optimal results. The investigators intend to investigate the optimization of benefits by using a novel hybrid FES cycling protocol (FES legs cycling plus voluntary arms cycling) combined with high intensity interval training (HIIT) and preceded by a preparatory muscle strengthening program called \"peripheral remodeling intermittent muscular exercise (PRIME) to prepare the deconditioned muscles for the more intense exercise in the hybrid HIIT-FES cycling program. The investigators hypothesize that individuals in the PRIME + hybrid HIIT-FES cycling program will demonstrate significantly greater cardiometabolic health and functional benefits than the control group receiving standard of care range of motion exercises.",[27],[550],"Hybrid functional electrical stimulation cycling","2026-06-30",{"date":553,"type":32},"2026-07-02",{"date":555,"type":32},"2026-03-03",{"date":557,"type":21},"2027-08-31",{"name":559,"class":39},"William Carey University",{"id":561,"slug":562,"hasResults":12,"nctId":563,"briefTitle":564,"officialTitle":565,"acronym":566,"eligibilityCriteria":567,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":427,"enrollmentInfo":568,"targetDuration":4,"studyType":22,"phases":569,"briefSummary":570,"conditions":571,"keywords":577,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":583,"lastUpdatePostDateStruct":584,"startDateStruct":586,"completionDateStruct":588,"leadSponsor":590,"locationsCount":40},"100644654","impact-of-transcutaneous-spinal-stimulation-on-blood-pressure-and-orthostasis-in-spinal-cord-injury-100644654","NCT07674511","Impact of Transcutaneous Spinal Stimulation on Blood Pressure and Orthostasis in Spinal Cord Injury","Impact of Transcutaneous Spinal Stimulation on Blood Pressure and Orthostasis in Spinal Cord Injury: Short and Long-Term Effects","(SCI)","Inclusion Criteria:\n\n* Individuals with a SCI ≥ 1 year after injury\n* Injury level ≥ T6 (thoracic level)\n* AIS grade A-C\n* Cardiovascular dysfunction characterized by one or more of the following:\n\n  1. Persistent hypotension (SBP \\\u003C 90mmHg)\n  2. Orthostatic hypotension (OH, a drop of 20\u002F10 mmHg in SBP\u002FDBP within 5 minutes of standing\u002Fupright positioning).\n\nAdditionally, experiencing orthostatic symptoms in daily life and\u002For requiring medication to manage OH.\n\nExclusion Criteria:\n\n* Current illness (e.g., infection, a pressure injury that might interfere with the intervention)\n* Ventilator-dependent\n* History of implanted brain\u002Fspine\u002Fnerve stimulators\n* Cardiac pacemaker\u002Fdefibrillator or intra-cardiac lines\n* Significant coronary artery or cardiac conduction disease, a recent history of myocardial infarction\n* History of seizures\n* pregnancy\n* Insufficient mental capacity to understand and independently provide consent\n* Deemed unsuitable by the study physician",{"count":429,"type":21},[24],"The purpose of this study is to learn whether stimulation applied to the spinal cord through the skin (called transcutaneous spinal stimulation) can help control blood pressure in people with a spinal cord injury.\n\nThe main questions this study attempts to solve:\n\n1. What are the immediate effects of spinal cord transcutaneous stimulation on BP?\n2. Does stimulation produce lasting improvements in BP regulation and subsequently, daily function?",[27,572,573,184,574,180,575,183,576],"Hypotension","Orthostatic Hypotension","Cardiovascular Diseases","Central Nervous System Disease","Blood Pressure",[578,579,580,581,582],"transcutaneous spinal cord stimulation","spinal stimulations","orthostatic hypotension","blood pressure","neuromodulation","2026-06-24",{"date":585,"type":32},"2026-06-29",{"date":587,"type":21},"2026-09",{"date":589,"type":21},"2028-12",{"name":591,"class":39},"Kessler Foundation",{"id":593,"slug":594,"hasResults":12,"nctId":595,"briefTitle":596,"officialTitle":597,"acronym":4,"eligibilityCriteria":598,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":427,"enrollmentInfo":599,"targetDuration":4,"studyType":22,"phases":601,"briefSummary":602,"conditions":603,"keywords":604,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":583,"lastUpdatePostDateStruct":606,"startDateStruct":608,"completionDateStruct":610,"leadSponsor":612,"locationsCount":40},"100571953","repetitive-transcranial-magnetic-stimulation-therapy-in-spinal-cord-injury-related-neuropathic-pain-100571953","NCT06726954","Repetitive Transcranial Magnetic Stimulation Therapy in Spinal Cord Injury Related Neuropathic Pain","Efficacy of Repetitive Transcranial Magnetic Stimulation Therapy in Neuropathic Pain Associated With Spinal Cord Injury; Randomized Controlled Trial","Inclusion Criteria:\n\nAged 18-75 years Physician-diagnosed spinal cord injury for at least 3-months Neuropathic pain for at least 3-months Pain not attributable to any other conditions\n\nExclusion Criteria:\n\n* Having an important comorbid disease such as severe heart disease (aortic stenosis, angina, hypertrophic cardiomyopathy, uncontrolled hypertension,arrhythmia, pacemaker)\n* Neurodegenerative disease\n* Epilepsy\n* History of antiepileptic drug use\n* Cognitive dysfunction\n* Lower extremity peripheral nerve injury\n* Increased intracranial pressure or uncontrolled migraine\n* Infection on the skin in the application area.\n* Having a brain lesion or a history of drug use that will affect the seizure threshold.\n\nAny TMS-related contraindications, for example:\n\n* Pacemaker\n* Metallic implant\n* Previous seizure\n* Psychiatric disorders (excluding depression and anxiety)\n* Malignancy\n* Current pregnancy",{"count":600,"type":21},63,[24],"The aim of our study is to investigate the effect of different protocols of high-frequency Repetitive Transcranial Magnetic Stimulation (rTMS) therapy added to the rehabilitation program on neuropathic pain,depression, quality of life and quality of sleep compared to each other and placebo group in participants with spinal cord injury.",[27,407],[605,176,407],"Transcranial Magnetic Stimulation",{"date":607,"type":32},"2026-06-26",{"date":609,"type":32},"2024-12-16",{"date":611,"type":21},"2026-12-30",{"name":613,"class":39},"Afyonkarahisar Health Sciences University",{"id":615,"slug":616,"hasResults":12,"nctId":617,"briefTitle":618,"officialTitle":619,"acronym":620,"eligibilityCriteria":621,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":252,"enrollmentInfo":622,"targetDuration":4,"studyType":22,"phases":624,"briefSummary":625,"conditions":626,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":630,"lastUpdatePostDateStruct":631,"startDateStruct":633,"completionDateStruct":635,"leadSponsor":637,"locationsCount":40},"100555426","feasibility-of-the-braingate2-neural-interface-system-in-persons-with-tetraplegia-bg-tablet-01-100555426","NCT06511934","Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia (BG-Tablet-01)","Intuitive, Complete Neural Control of Tablet Computers for Communication","BG-Tablet-01","Inclusion Criteria:\n\n* Clinical diagnosis of spinal cord injury, brainstem stroke, muscular dystrophy, amyotrophic lateral sclerosis or other motor neuron disorders\n* Complete or incomplete tetraplegia (quadriplegia)\n* Must live within a three-hour drive of the Study site\n* Prior enrollment in BrainGate2 clinical trial (NCT00912041)\n\nExclusion Criteria:\n\n* Visual impairment such that extended viewing of a computer monitor would be difficult even with ordinary corrective lenses\n* Chronic oral or intravenous steroids or immunosuppressive therapy\n* Other serious disease or disorder that could seriously affect ability to participate in the study\n\n(There are additional exclusion criteria)",{"count":623,"type":21},6,[24],"People with brainstem stroke, advanced amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's disease), or other disorders can become unable to move or speak despite being awake and alert. In this project, the investigators seek to further translate knowledge about interpreting brain signals related to movement, and to further develop an intracortical brain-computer interface (iBCI) that could restore rapid and intuitive use of communication apps on tablet computers by people with paralysis.",[627,628,433,27,629],"Brainstem Stroke","ALS","Cervical Spinal Cord Injury","2026-06-22",{"date":632,"type":32},"2026-06-25",{"date":634,"type":32},"2024-07-22",{"date":636,"type":21},"2027-07-30",{"name":638,"class":39},"Leigh R. Hochberg, MD, PhD.",{"id":640,"slug":641,"hasResults":12,"nctId":642,"briefTitle":643,"officialTitle":644,"acronym":4,"eligibilityCriteria":645,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":427,"enrollmentInfo":646,"targetDuration":4,"studyType":22,"phases":648,"briefSummary":649,"conditions":650,"keywords":651,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":657,"lastUpdatePostDateStruct":658,"startDateStruct":659,"completionDateStruct":661,"leadSponsor":662,"locationsCount":40},"100463679","phase-2-using-smartphones-to-improve-physical-activity-levels-of-individuals-with-spinal-cord-injury-100463679","NCT05317832","Using Smartphones to Improve Physical Activity Levels of Individuals With Spinal Cord Injury","mHealth-based Just-In-Time Adaptive Intervention to Improve Physical Activity Levels of Individuals With Spinal Cord Injury","Inclusion Criteria: Participants with SCI will be included if they are:\n\n* 18-75 years of age\n* have a traumatic or non-traumatic SCI (classification of neurological level of injury at cervical level 5 (C5) and below)\n* are at least 6-months post-SCI\n* use a manual or a power wheelchair as their primary means of mobility (\\>80% of time)\n* can use their arms to exercise\n* show readiness to physical activity as assessed by the Physical Activity Readiness Questionnaire\n* have experience using a smartphone and smartwatch.\n\nExclusion Criteria: Participants will be excluded if they have:\n\n* any secondary complications that medically restrict their activity in any way such as cardiovascular disease, pressure injuries, contractures, and infections\n* are diagnosed with traumatic brain injury.",{"count":647,"type":21},196,[172],"The overarching goal of this research study is to evaluate a sensor-enabled, just-in-time adaptive intervention (JITAI) strategy to increase and sustain physical activity levels among individuals with spinal cord injury (SCI) in their communities. A primary objective of this study is to evaluate the integration of a JITAI with a web-based physical activity intervention program. We hypothesize that the integration of web-based physical activity intervention program with JITAI will result in significantly higher physical activity levels compared to the standard web-based physical activity intervention program alone. A secondary objective of this study is to extend existing algorithms that use commercial wearable technology to robustly detect physical activity behaviors to facilitate the delivery of tailored just-in-time actionable feedback and physical activity recommendations for individuals with SCI.",[27],[652,653,654,655,656],"spinal cord injuries","physical activity","wearable sensors","mobile health","just-in-time adaptive intervention","2026-06-19",{"date":583,"type":32},{"date":660,"type":32},"2023-05-25",{"date":466,"type":21},{"name":663,"class":39},"Temple University",{"id":665,"slug":666,"hasResults":12,"nctId":667,"briefTitle":668,"officialTitle":668,"acronym":4,"eligibilityCriteria":669,"healthyVolunteers":308,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":670,"targetDuration":4,"studyType":672,"phases":4,"briefSummary":673,"conditions":674,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":675,"lastUpdatePostDateStruct":676,"startDateStruct":678,"completionDateStruct":680,"leadSponsor":682,"locationsCount":40},"100595234","development-of-a-novel-evaluation-scale-of-mental-body-representation-mbr-for-adults-with-spinal-cord-injury-100595234","NCT07029802","Development of a Novel Evaluation Scale of Mental Body Representation (MBR) for Adults With Spinal Cord Injury","Inclusion Criteria:\n\nControl group\n\n* Uninjured adults (from the contact list with the Brain Body Mind lab or through fliers or StudyFinder)\n* 18+ years old adults\n\nSCI group\n\n* 18+ years old, participants with an incomplete or complete SCI of ≥ 1 year\n* medically stable\n* able to read and understand English\n* having access to the internet\u002FiPad\u002Fcomputer\u002Fphone and willing to come in for an in-person testing at the University of Minnesota.\n\nExclusion Criteria:\n\nSCI group\n\n* Uncontrolled seizure disorder;\n* cognitive impairment and\u002For communicative disability (e.g., due to brain injury) preventing them from following directions or from learning;\n* ventilator dependency;\n* major medical complications;\n* pressure ulcers hindering prolonged sitting or lying down.",{"count":671,"type":21},80,"OBSERVATIONAL","The purpose of this study is twofold: (1) Develop a new evaluation scale for mental body representations (MBR, i.e., body awareness and visuospatial body maps) for adults with spinal cord injury (SCI) with and without neuropathic pain. (2) Assess the psychometric properties of usability, reliability, and validity of the new evaluation scale This is a cross-sectional observational study design. For Aim 1, this study will involve initial item generation for a novel MBR evaluation scale for SCI through email communication, and individual interviews proctored remotely through Zoom, or, if preferred by the participant, in-person. For Aim 2, the study will include a Zoom call for consenting and questionnaires, as well as an in-person visit where participants will be tested with the new SCI-BodyMap evaluation scale, and a questionnaire asking about the usability and satisfaction of the new evaluation scale.",[27],"2026-06-16",{"date":677,"type":32},"2026-06-18",{"date":679,"type":32},"2024-11-18",{"date":681,"type":21},"2027-06-15",{"name":62,"class":39}]